Trials / Completed
CompletedNCT00170729
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to demonstrate that two days of treatment with 0.5% prednisolone acetate eye-drops after cataract surgery are superior to vehicle in reducing the flare in the anterior chamber of the operated eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisolone acetate |
Timeline
- Start date
- 2004-08-17
- Primary completion
- 2005-02-28
- Completion
- 2005-02-28
- First posted
- 2005-09-15
- Last updated
- 2017-03-01
Source: ClinicalTrials.gov record NCT00170729. Inclusion in this directory is not an endorsement.